MicroBase Technology（3184）株式概要MicroBase Technology Corp.は台湾で患者や医療従事者にドラッグデリバリーシステムを提供している。 詳細3184 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金3/6報酬当社が推定した公正価値より42.3%で取引されている リスク分析TW市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( NT$858M )すべてのリスクチェックを見る3184 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW461,592 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA461,592 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$13.6022.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-156m329m2016201920222025202620282031Revenue NT$220.1mEarnings NT$45.6mAdvancedSet Fair ValueView all narrativesMicroBase Technology Corp. 競合他社Lagis EnterpriseSymbol: TPEX:6730Market cap: NT$1.2bSpirit ScientificSymbol: TPEX:7790Market cap: NT$955.3mBioptik Technology IncorporationSymbol: TPEX:4161Market cap: NT$1.4bCVC TechnologiesSymbol: TPEX:4744Market cap: NT$1.6b価格と性能株価の高値、安値、推移の概要MicroBase Technology過去の株価現在の株価NT$13.6052週高値NT$35.9052週安値NT$8.40ベータ0.561ヶ月の変化-3.55%3ヶ月変化-41.13%1年変化4.25%3年間の変化-27.06%5年間の変化-14.17%IPOからの変化-18.22%最新ニュースValuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$15.05, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 16x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 16% over the past three years.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$12.25, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 29% over the past three years.Upcoming Dividend • Jul 03Upcoming dividend of NT$0.22 per shareEligible shareholders must have bought the stock before 10 July 2026. Payment date: 31 July 2026. The company last paid an ordinary dividend in . The average dividend yield among industry peers is 3.7%.Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 9.6% over the past three years.Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years.New Risk • May 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m).最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$15.05, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 16x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 16% over the past three years.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$12.25, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 29% over the past three years.Upcoming Dividend • Jul 03Upcoming dividend of NT$0.22 per shareEligible shareholders must have bought the stock before 10 July 2026. Payment date: 31 July 2026. The company last paid an ordinary dividend in . The average dividend yield among industry peers is 3.7%.Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 9.6% over the past three years.Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years.New Risk • May 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m).Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$16.60, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 15% over the past three years.お知らせ • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026. Location: no,756, ch`ieh tung rd., bade district, taoyuan city TaiwanValuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 38%After last week's 38% share price gain to NT$19.70, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.9% over the past three years.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to NT$14.05, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$788.4m market cap, or US$25.1m).New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$750.6m market cap, or US$23.9m).Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 25%After last week's 25% share price gain to NT$11.85, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.New Risk • Aug 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$842.9m market cap, or US$28.2m).Reported Earnings • Apr 26Full year 2024 earnings released: EPS: NT$0.86 (vs NT$0.47 in FY 2023)Full year 2024 results: EPS: NT$0.86 (up from NT$0.47 in FY 2023). Revenue: NT$214.8m (up 10% from FY 2023). Net income: NT$69.4m (up 82% from FY 2023). Profit margin: 32% (up from 20% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$10.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 17% over the past three years.Buy Or Sell Opportunity • Apr 14Now 21% overvaluedOver the last 90 days, the stock has fallen 17% to NT$10.15. The fair value is estimated to be NT$8.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.お知らせ • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025. Location: no,756, ch`ieh tung rd., bade district, taoyuan city TaiwanBuy Or Sell Opportunity • Mar 28Now 22% overvaluedOver the last 90 days, the stock has fallen 23% to NT$10.40. The fair value is estimated to be NT$8.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$951.3m market cap, or US$28.9m).New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.12b market cap, or US$34.3m).Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$13.85, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.1% over the past three years.Reported Earnings • Apr 12Full year 2023 earnings released: EPS: NT$0.48 (vs NT$0.079 in FY 2022)Full year 2023 results: EPS: NT$0.48 (up from NT$0.079 in FY 2022). Revenue: NT$194.8m (up 6.8% from FY 2022). Net income: NT$38.1m (up 500% from FY 2022). Profit margin: 20% (up from 3.5% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Apr 03MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.01b market cap, or US$31.8m).New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.12b market cap, or US$35.3m).Reported Earnings • Apr 01Full year 2022 earnings released: EPS: NT$0.08 (vs NT$0.47 loss in FY 2021)Full year 2022 results: EPS: NT$0.08 (up from NT$0.47 loss in FY 2021). Revenue: NT$182.3m (down 14% from FY 2021). Net income: NT$6.35m (up NT$43.7m from FY 2021). Profit margin: 3.5% (up from net loss in FY 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 15First half 2022 earnings released: NT$0.03 loss per share (vs NT$0.11 loss in 1H 2021)First half 2022 results: NT$0.03 loss per share (up from NT$0.11 loss in 1H 2021). Revenue: NT$82.9m (down 26% from 1H 2021). Net loss: NT$2.17m (loss narrowed 75% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 13% per year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 18First half 2021 earnings released: NT$0.11 loss per share (vs NT$0.41 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: NT$111.6m (down 9.0% from 1H 2020). Net loss: NT$8.84m (loss narrowed 71% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.分析記事 • Apr 11Is MicroBase Technology (GTSM:3184) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Apr 11Full year 2020 earnings released: NT$0.95 loss per share (vs NT$0.75 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$249.8m (down 5.9% from FY 2019). Net loss: NT$74.0m (loss widened 51% from FY 2019). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 01New 90-day low: NT$12.75The company is down 34% from its price of NT$19.45 on 03 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 26% over the same period.Is New 90 Day High Low • Jan 15New 90-day low: NT$14.70The company is down 25% from its price of NT$19.50 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.Is New 90 Day High Low • Dec 22New 90-day low: NT$16.20The company is down 16% from its price of NT$19.40 on 24 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 13% over the same period.Is New 90 Day High Low • Dec 05New 90-day low: NT$17.45The company is down 9.0% from its price of NT$19.10 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 9.0% over the same period.分析記事 • Dec 01Is MicroBase Technology (GTSM:3184) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Nov 06New 90-day low: NT$18.90The company is down 8.0% from its price of NT$20.55 on 07 August 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 4.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day low: NT$19.00The company is down 7.0% from its price of NT$20.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 2.0% over the same period.株主還元3184TW Medical EquipmentTW 市場7D1.1%-1.3%-1.9%1Y4.3%-29.0%86.7%株主還元を見る業界別リターン: 3184過去 1 年間で-29 % の収益を上げたTW Medical Equipment業界を上回りました。リターン対市場: 3184は、過去 1 年間で86.7 % のリターンを上げたTW市場を下回りました。価格変動Is 3184's price volatile compared to industry and market?3184 volatility3184 Average Weekly Movement9.6%Medical Equipment Industry Average Movement4.6%Market Average Movement6.4%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.7%安定した株価: 3184の株価は、 TW市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 3184の weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてTWの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1997n/aTian Lai Liumicrobasetech.comMicroBase Technology Corp.は台湾で患者や医療専門家にドラッグデリバリーシステムを提供している。LIGA技術を用いた非シリコンベースのMEMSを開発し、小型デバイスやミクロン単位の部品の製造・開発に応用している。同社はまた、呼吸器疾患治療用の吸入デバイスであるポケットエアや、女性が自宅で使用するためのマイクロニードル製品であるファーマトリックスも提供している。マイクロベース・テクノロジー社は1997年に設立され、台湾桃園市に本社を置いている。もっと見るMicroBase Technology Corp. 基礎のまとめMicroBase Technology の収益と売上を時価総額と比較するとどうか。3184 基礎統計学時価総額NT$857.81m収益（TTM）NT$43.68m売上高(TTM)NT$210.93m19.6xPER（株価収益率4.1xP/Sレシオ3184 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計3184 損益計算書（TTM）収益NT$210.93m売上原価NT$101.16m売上総利益NT$109.77mその他の費用NT$66.09m収益NT$43.68m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）0.69グロス・マージン52.04%純利益率20.71%有利子負債／自己資本比率0%3184 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.6%現在の配当利回り32%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 16:49終値2026/08/20 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MicroBase Technology Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$15.05, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 16x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 16% over the past three years.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$12.25, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 29% over the past three years.
Upcoming Dividend • Jul 03Upcoming dividend of NT$0.22 per shareEligible shareholders must have bought the stock before 10 July 2026. Payment date: 31 July 2026. The company last paid an ordinary dividend in . The average dividend yield among industry peers is 3.7%.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 9.6% over the past three years.
Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years.
New Risk • May 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m).
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$15.05, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 16x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 16% over the past three years.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to NT$12.25, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 29% over the past three years.
Upcoming Dividend • Jul 03Upcoming dividend of NT$0.22 per shareEligible shareholders must have bought the stock before 10 July 2026. Payment date: 31 July 2026. The company last paid an ordinary dividend in . The average dividend yield among industry peers is 3.7%.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 9.6% over the past three years.
Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years.
New Risk • May 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m).
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$16.60, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 15% over the past three years.
お知らせ • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026. Location: no,756, ch`ieh tung rd., bade district, taoyuan city Taiwan
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 38%After last week's 38% share price gain to NT$19.70, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.9% over the past three years.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment improves as stock rises 24%After last week's 24% share price gain to NT$14.05, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$788.4m market cap, or US$25.1m).
New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$750.6m market cap, or US$23.9m).
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 25%After last week's 25% share price gain to NT$11.85, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years.
New Risk • Aug 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$842.9m market cap, or US$28.2m).
Reported Earnings • Apr 26Full year 2024 earnings released: EPS: NT$0.86 (vs NT$0.47 in FY 2023)Full year 2024 results: EPS: NT$0.86 (up from NT$0.47 in FY 2023). Revenue: NT$214.8m (up 10% from FY 2023). Net income: NT$69.4m (up 82% from FY 2023). Profit margin: 32% (up from 20% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$10.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 17% over the past three years.
Buy Or Sell Opportunity • Apr 14Now 21% overvaluedOver the last 90 days, the stock has fallen 17% to NT$10.15. The fair value is estimated to be NT$8.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.
お知らせ • Apr 02MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025. Location: no,756, ch`ieh tung rd., bade district, taoyuan city Taiwan
Buy Or Sell Opportunity • Mar 28Now 22% overvaluedOver the last 90 days, the stock has fallen 23% to NT$10.40. The fair value is estimated to be NT$8.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable.
New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$951.3m market cap, or US$28.9m).
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.12b market cap, or US$34.3m).
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$13.85, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.1% over the past three years.
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: NT$0.48 (vs NT$0.079 in FY 2022)Full year 2023 results: EPS: NT$0.48 (up from NT$0.079 in FY 2022). Revenue: NT$194.8m (up 6.8% from FY 2022). Net income: NT$38.1m (up 500% from FY 2022). Profit margin: 20% (up from 3.5% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Apr 03MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.01b market cap, or US$31.8m).
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.12b market cap, or US$35.3m).
Reported Earnings • Apr 01Full year 2022 earnings released: EPS: NT$0.08 (vs NT$0.47 loss in FY 2021)Full year 2022 results: EPS: NT$0.08 (up from NT$0.47 loss in FY 2021). Revenue: NT$182.3m (down 14% from FY 2021). Net income: NT$6.35m (up NT$43.7m from FY 2021). Profit margin: 3.5% (up from net loss in FY 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 15First half 2022 earnings released: NT$0.03 loss per share (vs NT$0.11 loss in 1H 2021)First half 2022 results: NT$0.03 loss per share (up from NT$0.11 loss in 1H 2021). Revenue: NT$82.9m (down 26% from 1H 2021). Net loss: NT$2.17m (loss narrowed 75% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 13% per year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 18First half 2021 earnings released: NT$0.11 loss per share (vs NT$0.41 loss in 1H 2020)The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: NT$111.6m (down 9.0% from 1H 2020). Net loss: NT$8.84m (loss narrowed 71% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
分析記事 • Apr 11Is MicroBase Technology (GTSM:3184) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Apr 11Full year 2020 earnings released: NT$0.95 loss per share (vs NT$0.75 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$249.8m (down 5.9% from FY 2019). Net loss: NT$74.0m (loss widened 51% from FY 2019). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 01New 90-day low: NT$12.75The company is down 34% from its price of NT$19.45 on 03 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 26% over the same period.
Is New 90 Day High Low • Jan 15New 90-day low: NT$14.70The company is down 25% from its price of NT$19.50 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.
Is New 90 Day High Low • Dec 22New 90-day low: NT$16.20The company is down 16% from its price of NT$19.40 on 24 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 13% over the same period.
Is New 90 Day High Low • Dec 05New 90-day low: NT$17.45The company is down 9.0% from its price of NT$19.10 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 9.0% over the same period.
分析記事 • Dec 01Is MicroBase Technology (GTSM:3184) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Nov 06New 90-day low: NT$18.90The company is down 8.0% from its price of NT$20.55 on 07 August 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day low: NT$19.00The company is down 7.0% from its price of NT$20.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 2.0% over the same period.
